ISAD × WHO day

Preliminary invited participants and draft program

Purpose and general structure of the day 1.

The ISAD × WHO day will be held on Friday, 16 October 2026, immediately before the Rajka Symposium in Beijing. It will provide a structured forum to advance two closely linked ISAD priorities in atopic dermatitis: the development of an international Treat-to-Target consensus project and the continuation of ISAD–WHO-related work on access to care and essential medicines.

All invited participants listed below are invited for the full day. The day will have two distinct formats:

1. Morning session – closed to industry

This session will be devoted to the ISAD-led Treat-to-Target consensus project in atopic dermatitis. It will focus on scope, terminology, methodology, patient-centered outcomes, global feasibility, and the next steps toward Delphi consensus development.

2. Afternoon session – open to industry

This session will review ongoing ISAD–WHO-related projects, access-to-medicines priorities, and preparation for the 2027 WHO Essential Medicines List cycle. Industry participants will be invited separately and may contribute actively during the moderated discussions.

A short report from the closed morning Treat-to-Target workshop will be presented during the afternoon session. A further concise report from the day will also be presented at the main Rajka meeting.

Preliminary invited participants by region of origin 2.

Roles of ISAD, IEC, GADA, WHO, ILDS, and Industry 3.

ISAD

ISAD will convene the meeting and coordinate the overall scientific agenda. ISAD will lead the Treat-to-Target consensus project, patient-centered discussions, regional guideline links, and reporting to the main Rajka meeting.

IEC

IEC will be involved throughout the day, especially in the Treat-to-Target consensus development and in ensuring alignment with international AD expertise.

GADA

GADA will contribute to global epidemiology, disease burden, metrics, and implementation perspectives of the T2T project. Through Carsten Flohr, GADA will also provide the operational link with ILDS for the access-to-medicines project.

WHO

WHO via Lorenzo Moja will contribute to the discussion on essential medicines and access to care, particularly in relation to the 2027 WHO Essential Medicines List process.

ILDS

ILDS, via Carsten Flohr/GADA, will be in command of the main project for possible inclusion of methotrexate and dupilumab in the 2027 WHO Essential Medicines List cycle (expected submission in September 2027).

Industry

Industry participants will be invited separately for the afternoon session. They will not participate in the closed morning workshop. In the afternoon, they will not be limited to observer status and may contribute actively during moderated discussions.

Preliminary program of the day

Please note all timings are based on Beijing time zone.
➜ China Standard Time (CST) – UTC+08:00

	Morning Session — 08:30 Closed to the Industry Treat-to-Target in Atopic Dermatitis: from concept to consensus methodology Rapporteurs: Andreas WOLLENBERG and John SU
08:30–09:00		Arrival and registration for closed workshop ISAD / local organizing team
09:00–09:10		Welcome and objectives of the ISAD × WHO day Alain Taïeb, Lin Ma, John Su
09:10–09:25		Why Treat-to-Target is needed in atopic dermatitis ISAD T2T steering group (ISAD-IEC, GADA)
09:25–09:45		Lessons from asthma, multidisciplinary care, and long-term control Frank Thien (pulmonologist)
09:45–10:10		Patient-reported outcomes, patient-centered medicine, pediatric aspects, “meaningful” disease control Kathy Gibson (Rheumatologist); Li-Chuen Wong (Pediatric dermatologist); patient representatives
15:35	BS2	Break Session 2 (free time without presentation)55 min. Refreshment Break & Visit Exhibits ➜ Check the Schedule
10:30–10:55		Mapping/ Scoping review for the AD T2T consensus process Maria Kinberger / Charité methodology team
10:55–11:20		Proposing candidate domains: signs, symptoms, sleep, quality of life, flares, treatment burden, safety concerns, and patient priorities ISAD / IEC / GADA contributors
11:20–11:50		Global feasibility: adapting targets across high-, middle-, and low-resource settings GADA, African and Asian guideline task force representatives
11:50–12:20		Roundtable: scope, terminology, Delphi structure, governance, and next steps ISAD, IEC, GADA, patients, methodologists
12:20–12:30		Rapporteurs’ summary and agreed points for afternoon report Andreas Wollenberg and John Su
12:30–13:30		Lunch Full-day invited participants

Morning reporting:

The morning output should include a concise set of agreed points on:

1. The scope of the T2T consensus project;
2. The domains to be considered in the Delphi process;
3. The role of patient-centered outcomes and PROMs;
4. The global feasibility of proposed targets;
5. The governance and timeline for the next phases of the project.

	Afternoon Session — 13:30 Open to the Industry ISAD–WHO projects, access to care, and the 2027 WHO Essential Medicines List perspective
13:30–13:40		Welcome to the open afternoon session ISAD / WHO / Lin Ma (Beijing Rajka local host)
13:40–14:00		Short report from the closed morning T2T workshop Andreas Wollenberg, John Su, Alain Taïeb
14:00–14:25		ISAD–WHO collaboration: progress since Melbourne and priorities for 2026–2027 ISAD / WHO contributors
14:25–15:00		Essential Medicines for atopic dermatitis: lessons from emollients and preparation for the next EML cycles Lorenzo Moja; Marie Lodén; ISAD access group
15:00–15:30		ILDS-led project for the next EML cycle: methotrexate and dupilumab Carsten Flohr for ILDS/ ISAD, IEC and other contributors
15:35	BS2	Break Session 2 (free time without presentation)55 min. Refreshment Break & Visit Exhibits ➜ Check the Schedule
15:50–16:20		Discussion on access to topical/systemic treatments in AD: evidence, affordability, and implementation challenges across settings All
16:20–16:45		Regional perspectives on AD care and access: Africa, Asia-Pacific, Middle East, and Latin America Erere Otrofanowei; Sandipan Dhar; Javier Arellano; Roberto Takaoka; Middle East representatives
16:45–17:10		Patient priorities, patient-centered medicine, safety concerns, access, and communication Roberto Takaoka; patient representatives and advocacies
17:10–17:35		Moderated discussion with industry participants: evidence generation, affordability, responsible access, and global AD care Open moderated discussion; industry contributors welcome
17:35–17:50		Summary of action points: T2T consensus, EML 2027, regional guidelines, and patient engagement Alain Taïeb with session rapporteurs
17:50–18:00		Closing remarks and preparation of short report for the main Rajka meeting Alain Taïeb, Lin Ma, John Su

Afternoon and main-meeting reporting:

Alain TAÏEB will report the key points at the main Rajka meeting, including a short report from the closed morning T2T workshop and the main conclusions from the afternoon session, as part of ISAD president’s annual report.

Expected outputs of the day 4.

The expected outputs of the ISAD × WHO day are:

1. A clear statement of the scope and next steps of the ISAD Treat-to-Target consensus project.
2. Agreement on the main domains to be considered in the Delphi process.
3. Integration of patient-centered medicine and patient-reported outcomes into the T2T framework.
4. A short internal report from the closed morning workshop.
5. A shared update on ISAD–WHO-related projects and access-to-care priorities.
6. 2027 EML strategy for AD, including the ILDS project on methotrexate and dupilumab, and projects for EML 2029
7. Regional input on implementation challenges in Africa, Asia-Pacific, the Middle East, and Latin America.
8. A structured discussion with industry participants on evidence generation, affordability, responsible access, and global AD care.
9. A concise report to be presented at the main Rajka meeting on Monday 19th (afternoon).

Points still to be completed 5.

1. Add the industry participant list when available.
2. Confirm final availability of all invited participants.
3. Confirm the final local Chinese host roles.